EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chiu, Y. J.
Right arrow Articles by Reid, I. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiu, Y. J.
Right arrow Articles by Reid, I. A.
Experimental Biology and Medicine 227:620-625 (2002)
© 2002 Society for Experimental Biology and Medicine


ORIGINAL ARTICLE

Effect of Sildenafil on Renin Secretion in Human Subjects

Yeong Jen Chiu* and Ian A. Reid{dagger},1

* Y.J. Chiu General Hospital, Kaohsiung, Taiwan; and
{dagger} Department of Physiology, University of California, San Francisco, San Francisco, CA

Sildenafil is a potent and selective inhibitor of the cyclic GMP-specific phosphodiesterase (PDE5) that is very effective in the treatment of male impotence. It inhibits breakdown of cyclic guanosine monophosphate (cGMP) formed in penile smooth muscle cells in response to stimulation by nitric oxide resulting in muscle relaxation. PDE5 is widely distributed in the body, being present in the vasculature, platelets, and kidneys. In the kidney, PDE5 is involved in the regulation of sodium excretion and renin secretion. The aim of the present investigation was to investigate the effect of sildenafil, in doses used clinically, on renin secretion in human subjects. The studies were performed in two groups of healthy normotensive subjects: one in which sodium intake was unrestricted, and one in which sodium intake was restricted to 600 mg/day. Blood pressure and heart rate were monitored throughout the study, and blood samples for the measurement of plasma cGMP and cAMP concentrations and plasma renin activity (PRA) were collected. After control measurements, the subjects ingested a capsule containing sildenafil or placebo. Cardiovascular measurements and blood sampling continued for the next 120 min. Sildenafil had only minor cardiovascular effects. Diastolic pressure tended to be lower and heart rate was generally higher after sildenafil than after placebo, but the differences were small. Sildenafil caused a prompt and sustained increase in plasma cGMP concentration and a more gradual increase in plasma cAMP concentration. After the subjects received placebo, there was a progressive decrease in PRA during the 2-hr observation period, presumably reflecting the circadian rhythm in renin secretion. In contrast, PRA failed to decrease after the subjects received sildenafil, thus indicating that sildenafil exerts a stimulatory action on renin secretion. This action on renin secretion may help explain why sildenafil only has minor effect on blood pressure despite the widespread distribution of PDE5 in vascular tissues.

Key Words: Viagra • sildenafil • phosphodiesterase • PDE5 inhibitor • renin secretion • cGMP • cAMP • blood pressure • heart rate




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. E. Teixeira, F. B. M. Priviero, and R. C. Webb
Differential Effects of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 654 - 661.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
H. C. Thiesson, B. L. Jensen, B. Jespersen, O. B. Schaffalitzky de Muckadell, C. Bistrup, S. Walter, P. D. Ottosen, A. Veje, and O. Skott
Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites
Am J Physiol Renal Physiol, May 1, 2005; 288(5): F1044 - F1052.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. M. Gardiner, J. E. March, P. A. Kemp, S. A. Ballard, E. Hawkeswood, B. Hughes, and T. Bennett
Hemodynamic Effects of Phosphodiesterase 5 and Angiotensin-Converting Enzyme Inhibition Alone or in Combination in Conscious SHR
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 265 - 271.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Experimental Biology and Medicine.